YU78795A - PEPTID p277 ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRŽE - Google Patents

PEPTID p277 ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRŽE

Info

Publication number
YU78795A
YU78795A YU78795A YU78795A YU78795A YU 78795 A YU78795 A YU 78795A YU 78795 A YU78795 A YU 78795A YU 78795 A YU78795 A YU 78795A YU 78795 A YU78795 A YU 78795A
Authority
YU
Yugoslavia
Prior art keywords
analysis
peptid
products containing
pharmaceutical products
peptide
Prior art date
Application number
YU78795A
Other languages
English (en)
Inventor
Irun R. Cohen
Dana Elias
Matityahu Fridkin
Original Assignee
Yeda Research And Development Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26322965&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU78795(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL11209494A external-priority patent/IL112094A0/xx
Priority claimed from IL11446095A external-priority patent/IL114460A0/xx
Application filed by Yeda Research And Development Co.Ltd. filed Critical Yeda Research And Development Co.Ltd.
Publication of YU78795A publication Critical patent/YU78795A/sh
Publication of RS49517B publication Critical patent/RS49517B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PEPTID p277 ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRŽE - Peptid koji ima strukturu p277 sekvence hsp60 u kojoj su oba cisteinska ostatka zamenjena u valinskim ostacima ili u kojoj je Thr19 ostatak zamenjen sa Lys ostatkom ima uglavnom istu biološku aktivnost kao p277 ali sa znatno poboljšanom stabilnošću. Novi p277 analozi mogu se koristiti za sve svrhe za koje se može koristiti i p277.
YU78795A 1994-12-21 1995-12-21 PEPTID p277-ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRZE RS49517B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11209494A IL112094A0 (en) 1994-12-21 1994-12-21 Novel peptides and pharmaceutical compositions comprising them
IL11446095A IL114460A0 (en) 1995-07-05 1995-07-05 Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes

Publications (2)

Publication Number Publication Date
YU78795A true YU78795A (sh) 1998-05-15
RS49517B RS49517B (sr) 2006-10-27

Family

ID=26322965

Country Status (31)

Country Link
EP (1) EP0820303B1 (sh)
JP (2) JP3420245B2 (sh)
KR (1) KR100400480B1 (sh)
CN (1) CN1233417C (sh)
AR (1) AR002949A1 (sh)
AT (1) ATE242005T1 (sh)
AU (1) AU707835B2 (sh)
BR (1) BR9510102A (sh)
CA (1) CA2208274C (sh)
CZ (1) CZ293784B6 (sh)
DE (2) DE820303T1 (sh)
DK (1) DK0820303T3 (sh)
ES (1) ES2201137T3 (sh)
FI (1) FI118373B (sh)
HR (1) HRP950612B1 (sh)
HU (1) HU224160B1 (sh)
IL (1) IL116499A0 (sh)
IS (1) IS1966B (sh)
MX (1) MX9704738A (sh)
NO (1) NO317350B1 (sh)
NZ (1) NZ301440A (sh)
PL (1) PL184145B1 (sh)
PT (1) PT820303E (sh)
RO (1) RO116777B1 (sh)
RS (1) RS49517B (sh)
SI (1) SI0820303T1 (sh)
TR (1) TR199501630A2 (sh)
TW (1) TW496872B (sh)
UA (1) UA42040C2 (sh)
UY (1) UY24130A1 (sh)
WO (1) WO1996019236A1 (sh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
DE69724619T2 (de) * 1996-05-14 2004-07-01 Winnacker, Ernst-Ludwig, Prof. Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
EP1335741A4 (en) * 2000-08-25 2005-10-26 Yeda Res & Dev METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02)
IL140233A0 (en) * 2000-12-11 2002-02-10 Peptor Ltd Backbone cyclized analogs of heat shock proteins
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
CA2595520A1 (en) 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
DE102004043750A1 (de) * 2004-09-10 2006-03-30 Sanofi-Aventis Deutschland Gmbh Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität
CN100352502C (zh) * 2004-12-29 2007-12-05 中国药科大学 能通过免疫防治ⅰ型糖尿病的重组蛋白和重组基因
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP2295066B1 (en) 2005-05-25 2016-04-27 CureDM Group Holdings, LLC Peptides, derivatives and analogs thereof, and methods of using same
JP4283812B2 (ja) * 2006-01-06 2009-06-24 財団法人工業技術研究院 重症筋無力症の診断方法およびそのキット
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
MX337147B (es) 2007-08-30 2016-02-15 Curedm Group Holdings Llc Composiciones y metodos para utilizar peptidos proislet y sus analogos.
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
WO2013128450A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
CN104418948B (zh) * 2013-09-10 2019-08-16 深圳翰宇药业股份有限公司 一种制备多肽药物的方法
CN104650209B (zh) * 2013-11-19 2018-04-06 深圳翰宇药业股份有限公司 多肽药物DiaPep277 的合成方法
CN104650244B (zh) * 2015-01-21 2017-12-08 中国药科大学 一种具有降血糖兼调脂作用的表位组合肽及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
KR100400480B1 (ko) 2003-12-31
RS49517B (sr) 2006-10-27
UY24130A1 (es) 1996-06-11
NO972849D0 (no) 1997-06-19
WO1996019236A1 (en) 1996-06-27
JPH10511649A (ja) 1998-11-10
FI972669A (fi) 1997-08-15
MX9704738A (es) 1997-10-31
CA2208274C (en) 2005-12-06
HU224160B1 (hu) 2005-06-28
ES2201137T3 (es) 2004-03-16
TW496872B (en) 2002-08-01
FI972669A0 (fi) 1997-06-19
AR002949A1 (es) 1998-05-27
NO317350B1 (no) 2004-10-18
IS1966B (is) 2004-12-15
PL321091A1 (en) 1997-11-24
EP0820303A1 (en) 1998-01-28
PL184145B1 (pl) 2002-09-30
IS4510A (is) 1997-06-19
JP3420245B2 (ja) 2003-06-23
HRP950612B1 (en) 2003-12-31
SI0820303T1 (en) 2003-10-31
DE69531004D1 (de) 2003-07-10
JP3554319B2 (ja) 2004-08-18
AU707835B2 (en) 1999-07-22
CA2208274A1 (en) 1996-06-27
AU4686696A (en) 1996-07-10
NZ301440A (en) 2000-01-28
EP0820303B1 (en) 2003-06-04
HUT78092A (hu) 1999-09-28
HRP950612A2 (en) 1997-10-31
RO116777B1 (ro) 2001-06-29
PT820303E (pt) 2003-10-31
IL116499A0 (en) 1996-03-31
TR199501630A2 (tr) 1996-07-21
ATE242005T1 (de) 2003-06-15
DK0820303T3 (da) 2003-10-06
DE69531004T2 (de) 2004-02-05
JP2004026797A (ja) 2004-01-29
DE820303T1 (de) 1999-05-20
UA42040C2 (uk) 2001-10-15
CZ190897A3 (en) 1997-11-12
BR9510102A (pt) 1997-11-25
NO972849L (no) 1997-08-13
FI118373B (fi) 2007-10-31
CN1175214A (zh) 1998-03-04
CN1233417C (zh) 2005-12-28
EP0820303A4 (sh) 1998-03-11
CZ293784B6 (cs) 2004-07-14

Similar Documents

Publication Publication Date Title
YU78795A (sh) PEPTID p277 ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRŽE
Zoon et al. Amino terminal sequence of the major component of human lymphoblastoid interferon
Crawford et al. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens.
NO953033L (no) Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
DE69326064T2 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DK0935609T3 (da) Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ES2138973T3 (es) Muteinas de il-6 exentas de cisteina.
HUP0401536A2 (hu) Peptidek és/vagy proteinek, valamint terápiás és/vagy megelőző gyógyszerkészítmény előállítására történő alkalmazásuk
ATE365542T1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
NO914720L (no) Somatotropiner med forandringer i alfa-spiral-3-omraadet, alfa-spiral-2-omraadekombinasjoner derav og i kombinasjon medandre mutasjoner
KR940703858A (ko) 신규 거핵구 증폭인자(novel megakaryocyte amplifier)
ATE103294T1 (de) Peptidfragmente von hiv.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
ES2057579T3 (es) Peptidos e1 y c de rubeola.
HRP20041178B1 (hr) Muteini placentalnog faktora rasta tipa 1, metode njihove pripreme i primjene
Conroy et al. Structural features and biologic properties of fragments obtained by limited proteolysis of C3
BR0008370A (pt) Proteìnas de fusão de glicose deshidrogenase e uso das mesmas em sistemas de expressão
Blackwell et al. Fast hemoglobin variant in Minahassan people of Sulawesi, Chinese and Thais: α2β256 Gly→ Asp
ES2194008T3 (es) Proteina p100 del virus del herpes humano tipo 6, las correspondientes secuencias de adn, su preparacion y uso.
YU64192A (sh) Analozi insulina